Top-Rated StocksTop-RatedNASDAQ:ORKA Oruka Therapeutics (ORKA) Stock Price, News & Analysis $15.12 +0.72 (+5.00%) As of 09:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Oruka Therapeutics Stock (NASDAQ:ORKA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oruka Therapeutics alerts:Sign Up Key Stats Today's Range$14.10▼$14.9950-Day Range$10.90▼$15.5052-Week Range$5.49▼$52.32Volume181,811 shsAverage Volume136,530 shsMarket Capitalization$566.26 millionP/E RatioN/ADividend YieldN/APrice Target$40.38Consensus RatingBuy Company Overview Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA. Read More Oruka Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreORKA MarketRank™: Oruka Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 603rd out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingOruka Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOruka Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Oruka Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Oruka Therapeutics are expected to grow in the coming year, from ($3.41) to ($2.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oruka Therapeutics is -5.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oruka Therapeutics is -5.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOruka Therapeutics has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ORKA. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOruka Therapeutics does not currently pay a dividend.Dividend GrowthOruka Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ORKA. News and Social Media1.0 / 5News Sentiment-0.23 News SentimentOruka Therapeutics has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Oruka Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ORKA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Oruka Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oruka Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.69% of the stock of Oruka Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.44% of the stock of Oruka Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Oruka Therapeutics' insider trading history. Receive ORKA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oruka Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ORKA Stock News HeadlinesHC Wainwright Issues Negative Estimate for ORKA EarningsAugust 22 at 2:29 AM | americanbankingnews.comOruka Therapeutics initiated with a Buy at Clear StreetAugust 21 at 3:41 AM | msn.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.August 22 at 2:00 AM | Timothy Sykes (Ad)HC Wainwright Reiterates Buy Rating for Oruka Therapeutics (NASDAQ:ORKA)August 20 at 2:19 AM | americanbankingnews.comOruka Therapeutics (ORKA) Receives a Buy from H.C. WainwrightAugust 19 at 2:23 PM | theglobeandmail.comOruka Therapeutics (NASDAQ:ORKA) Rating Lowered to "Sell" at Wall Street ZenAugust 18, 2025 | americanbankingnews.comQ3 EPS Estimate for Oruka Therapeutics Lowered by AnalystAugust 17, 2025 | americanbankingnews.comOruka Therapeutics (NASDAQ:ORKA) Is In A Good Position To Deliver On Growth PlansAugust 15, 2025 | finance.yahoo.comSee More Headlines ORKA Stock Analysis - Frequently Asked Questions How have ORKA shares performed this year? Oruka Therapeutics' stock was trading at $19.39 on January 1st, 2025. Since then, ORKA shares have decreased by 23.7% and is now trading at $14.79. How were Oruka Therapeutics' earnings last quarter? Oruka Therapeutics, Inc. (NASDAQ:ORKA) announced its quarterly earnings data on Monday, August, 11th. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.02. Who are Oruka Therapeutics' major shareholders? Oruka Therapeutics' top institutional investors include Braidwell LP (4.07%), Franklin Resources Inc. (2.71%), Geode Capital Management LLC (1.89%) and Affinity Asset Advisors LLC (1.61%). View institutional ownership trends. How do I buy shares of Oruka Therapeutics? Shares of ORKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oruka Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oruka Therapeutics investors own include Astria Therapeutics (ATXS), Aldeyra Therapeutics (ALDX), Black Diamond Therapeutics (BDTX), Energy Transfer (ET), Heron Therapeutics (HRTX), Skye Bioscience (SKYE) and NuScale Power (SMR). Company Calendar Last Earnings8/11/2025Today8/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ORKA Previous SymbolNASDAQ:ORKA CIK907654 Webwww.arcabio.com Phone720-940-2100Fax720-208-9261EmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Oruka Therapeutics$40.38 High Price Target$49.00 Low Price Target$20.00 Potential Upside/Downside+173.0%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($2.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-26.26% Return on Assets-24.16% Debt Debt-to-Equity RatioN/A Current Ratio27.42 Quick Ratio27.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.10 per share Price / Book1.63Miscellaneous Outstanding Shares37,450,000Free Float28,204,000Market Cap$553.89 million OptionableN/A Beta-0.35 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:ORKA) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.